# Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

> **NCT00227019** · PHASE2 · COMPLETED · sponsor: **Heather Wakelee** · enrollment: 16 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Lung Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Pemetrexed
- **DRUG:** Vitamin B12
- **DRUG:** Folate
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00227019
- **Lead sponsor:** Heather Wakelee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-11
- **Final completion:** 2016-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227019, "Phase 2 Trial of Bevacizumab in Combination With Pemetrexed". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00227019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*